Objective, but not subjective, daytime sleepiness predicts mortality in obstructive sleep apnea
Abstract
STUDY OBJECTIVES: Obstructive sleep apnea (OSA) with objective but not subjective excessive daytime sleepiness (EDS) has been reported to be associated with cardiovascular comorbidity. We aimed to investigate the association between OSA with objective or subjective EDS and mortality in a general population sample.
METHODS: In this retrospective cohort study, we included 244 subjects with OSA and 553 subjects without OSA with a median follow-up duration of 8 years. Objective EDS was defined based on a mean latency value of the multiple sleep latency test (MSL) ≤ 8 min. Subjective EDS was defined based on the total score of the Epworth Sleepiness Scale > 10.
RESULTS: After adjusting for potential confounders, OSA with objective EDS was associated with an approximately 2.5-fold higher risk of all-cause mortality (hazard ratio [HR] = 2.451, 95% confidence interval [95% CI] = 1.319 to 4.556) and 3.9-fold higher risk of CVD mortality (HR = 3.876, 95% CI = 1.293 to 11.622) compared to subjects without OSA or objective EDS. Furthermore, subjects with OSA, objective EDS, and CVD at baseline had about a 2.9-fold higher risk of all-cause mortality (HR = 2.872, 95% CI = 1.186 to 6.953) compared to subjects without OSA, objective EDS, or CVD at baseline. In contrast, OSA with subjective EDS was not associated with increased hazard of all cause or CVD mortality.
CONCLUSIONS: Objective EDS appears to be an important marker of the biological severity of OSA. Future studies to validate the…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 553 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.